Trial Profile
Phase 2, Randomized, Double-Blind, Multiple-Dose Level, Placebo Controlled, Single Intravenous Dose, Parallel Efficacy and Safety Study of NRX-1074 in Subjects With Major Depressive Disorder
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Apimostinel (Primary)
- Indications Major depressive disorder
- Focus Therapeutic Use
- Sponsors Naurex
- 22 Jun 2015 According to a Naurex Inc. media release, the results of this trial will be presented at the 55th Annual Meeting of the American Society of Clinical Psychopharmacology (ASCP).
- 22 May 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 12 May 2015 According to Naurex media release, the data from this trial will be presented at 70th Annual Scientific Meeting of the Society of Biological Psychiatry (SOBP), held at the Fairmont Royal York Hotel in Toronto.